Twist Bioscience (NASDAQ:TWST) Reaches New 52-Week Low Following Analyst Downgrade

Twist Bioscience Co. (NASDAQ:TWSTGet Rating) shares reached a new 52-week low during mid-day trading on Thursday after Barclays lowered their price target on the stock from $75.00 to $60.00. The stock traded as low as $37.73 and last traded at $38.18, with a volume of 13534 shares changing hands. The stock had previously closed at $39.69.

TWST has been the subject of several other reports. Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, March 10th. The Goldman Sachs Group decreased their target price on Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating for the company in a report on Wednesday, April 13th. SVB Leerink cut their price target on shares of Twist Bioscience from $110.00 to $70.00 and set a “market perform” rating on the stock in a report on Monday, February 7th. Finally, Robert W. Baird decreased their price objective on shares of Twist Bioscience from $113.00 to $70.00 in a research note on Monday, February 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience currently has an average rating of “Buy” and an average target price of $63.75.

In other Twist Bioscience news, insider Patrick John Finn sold 659 shares of Twist Bioscience stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $60.52, for a total value of $39,882.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Thorburn sold 4,442 shares of the stock in a transaction dated Tuesday, February 22nd. The stock was sold at an average price of $52.52, for a total transaction of $233,293.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,119 shares of company stock valued at $1,138,306. 3.10% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in TWST. Concord Wealth Partners raised its position in Twist Bioscience by 227.9% during the fourth quarter. Concord Wealth Partners now owns 459 shares of the company’s stock worth $36,000 after acquiring an additional 319 shares during the period. EverSource Wealth Advisors LLC acquired a new stake in Twist Bioscience in the 4th quarter worth about $39,000. Windsor Creek Advisors LLC purchased a new stake in Twist Bioscience during the 3rd quarter worth approximately $43,000. KRS Capital Management LLC acquired a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $46,000. Finally, AdvisorNet Financial Inc lifted its position in shares of Twist Bioscience by 86.6% in the fourth quarter. AdvisorNet Financial Inc now owns 1,508 shares of the company’s stock valued at $117,000 after acquiring an additional 700 shares in the last quarter. 98.81% of the stock is owned by institutional investors and hedge funds.

The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -10.21 and a beta of 0.89. The stock has a 50 day moving average price of $48.35 and a 200-day moving average price of $74.43.

Twist Bioscience (NASDAQ:TWSTGet Rating) last announced its quarterly earnings data on Friday, February 4th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.17. The company had revenue of $42.00 million for the quarter, compared to analyst estimates of $38.22 million. Twist Bioscience had a negative return on equity of 27.10% and a negative net margin of 112.70%. The firm’s revenue for the quarter was up 48.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.72) EPS. On average, equities analysts anticipate that Twist Bioscience Co. will post -4.97 earnings per share for the current year.

About Twist Bioscience (NASDAQ:TWST)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.